Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.80 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.80 |
| ▸ | CLK1 | P49759 | 3/20 | 0.80 |
| ▸ | CLK3 | P49761 | 3/20 | 0.80 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | PIM1 | P11309 | 2/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.80 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.80 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 0.80 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.80 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.80 |
| ▸ | CLK2 | P49760 | 2/20 | 0.80 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | HTT | P42858 | 2/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.80 |
| ▸ | GAA | P10253 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018924 | 1.00 | DYRK1A (0.80) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL2977826 | 0.89 | DYRK1A (1.00) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL2977830 | 0.89 | DYRK1A (1.00) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL24718932 | 0.88 | DYRK1A (0.80) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL4012716 | 0.84 | CLK1 (0.72) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL4012236 | 0.84 | DYRK1A (0.67) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL4012725 | 0.84 | CLK1 (0.72) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL4012239 | 0.84 | DYRK1A (0.67) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL4013825 | 0.82 | CLK1 (0.74) | DYRK1ACSNK1ECLK1CLK3DYRK1B | |
| SCHEMBL4013820 | 0.82 | CLK1 (0.74) | DYRK1ACSNK1ECLK1CLK3DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116376745-A | Human-derived high-temperature-resistant bifidobacterium longum and application thereof | 上海承葛医药科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2025-02-27 | — | — | US | disclosed |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-20240245806-A1 | TREATMENT OF NEURODEGENERATIVE DISEASE USING CSA- AND INDY-TYPE COMPOUNDS | BROWN UNIVERSITY | 2024-07-25 | — | — | US | disclosed |
| CN-117653740-A | Antibody drug conjugates for ablating hematopoietic stem cells | 诺华股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110099697-B | Antibody drug conjugates for ablating hematopoietic stem cells | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023140846-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | FELICITEX THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230226061-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | FELICITEX THERAPUETICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| CN-116376745-A | Human-derived high-temperature-resistant bifidobacterium longum and application thereof | 上海承葛医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116376745-A | Human-derived high-temperature-resistant bifidobacterium longum and application thereof | 上海承葛医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2022251565-A1 | TREATMENT OF NEURODEGENERATIVE DISEASE USING CSA- AND INDY-TYPE COMPOUNDS | BROWN UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220305134-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-09-29 | — | — | US | disclosed |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | UNIV LIMERICK (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | UNIV LIMERICK (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | UNIV LIMERICK (IE) | 2017-10-05 | — | — | US | disclosed |
| WO-2009085226-A2 | INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085226-A2 | INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226061-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | KRAS, BRAF, RAF1 | DYRK1A 12/4885CSNK1E 311/4885CLK1 156/4885 |
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | DYRK1A 552/4885CSNK1E 316/4885CLK1 991/4885 |
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | ABL1, BCR, CD47 | DYRK1A 1460/4885CSNK1E 231/4885CLK1 2670/4885 |
| US-20220305134-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | DYRK1A 1623/4885CSNK1E 209/4885CLK1 2709/4885 |
| US-20240245806-A1 | TREATMENT OF NEURODEGENERATIVE DISEASE USING CSA- AND INDY-TYPE COMPOUNDS | GAP43, NLN, INA | DYRK1A 361/4885CSNK1E 1366/4885CLK1 1299/4885 |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | BUB1B, BUB1, CCNB1 | DYRK1A 999/4885CSNK1E 366/4885CLK1 583/4885 |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | IAPP, GPR119, INSR | DYRK1A 1775/4885CSNK1E 496/4885CLK1 370/4885 |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | BCR, ABL1, CD47 | DYRK1A 1623/4885CSNK1E 209/4885CLK1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.